Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOSHE YAIR LEVY

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1518059807
CMS profile
833077
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$775,978.99

666 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 6 of 14; records 251–300 of 666 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOSHE YAIR LEVY

NPI 1518059807 · CMS profile ID 833077

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 14; records 251–300 of 666 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518059807?year=2023&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOSHE YAIR LEVY, NPI 1518059807, CMS profile ID 833077. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 14; records 251–300 of 666 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518059807?year=2023&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MOSHE YAIR LEVY, NPI 1518059807, CMS profile ID 833077. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 14; records 251–300 of 666 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518059807?year=2023&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MOSHE YAIR LEVY, NPI 1518059807, CMS profile ID 833077, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 14; records 251–300 of 666 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1518059807?year=2023&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

666 matching records · $775,978.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 666 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 666.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $23.4508/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006509683 CMS
Ipsen Biopharmaceuticals, Inc $10.7508/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045410159 CMS
Ipsen Biopharmaceuticals, Inc $6,090.0008/29/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045410165 CMS
ABBVIE INC. $13.7608/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761519 CMS
ABBVIE INC. $97.0508/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761521 CMS
ABBVIE INC. $27.5708/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761523 CMS
ABBVIE INC. $44.0108/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761525 CMS
ABBVIE INC. $929.7908/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761527 CMS
ABBVIE INC. $3.7508/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761529 CMS
ABBVIE INC. $14.9708/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761531 CMS
ABBVIE INC. $50.0008/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761533 CMS
ABBVIE INC. $169.6708/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761515 CMS
ABBVIE INC. $192.6608/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761517 CMS
Celgene Corporation $24.0908/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211305 CMS
SOBI, INC $3,080.0008/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038137322 CMS
SOBI, INC $3,080.0008/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038137327 CMS
ABBVIE INC. $24.9708/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997761513 CMS
E.R. Squibb & Sons, L.L.C. $32.7508/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211339 CMS
E.R. Squibb & Sons, L.L.C. $46.3008/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211345 CMS
E.R. Squibb & Sons, L.L.C. $18.4808/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211351 CMS
E.R. Squibb & Sons, L.L.C. $4,447.0008/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211825 CMS
Adaptive Biotechnologies Corporation $19.5708/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022978817 CMS
CTI BioPharma Corp. $3,300.0008/22/2023 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039694271 CMS
CTI BioPharma Corp. $11.5508/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039694275 CMS
CTI BioPharma Corp. $121.9408/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039694279 CMS
Novartis Pharmaceuticals Corporation $20.5108/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991987407 CMS
Amgen Inc. $819.6108/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020645377 CMS
Incyte Corporation $21.8108/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044480079 CMS
JAZZ PHARMACEUTICALS INC. $37.4408/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058409939 CMS
Kite Pharma, Inc. $790.0008/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270923 CMS
Rigel Pharmaceuticals, Inc. $9.3208/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033416185 CMS
Amgen Inc. $224.0008/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020645335 CMS
Amgen Inc. $337.8108/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020645337 CMS
Amgen Inc. $263.7208/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020645381 CMS
E.R. Squibb & Sons, L.L.C. $100.2208/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211269 CMS
E.R. Squibb & Sons, L.L.C. $43.5508/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211287 CMS
E.R. Squibb & Sons, L.L.C. $33.3308/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211867 CMS
Incyte Corporation $4,920.0008/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044480619 CMS
Stemline Therapeutics Inc. $119.9908/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040033857 CMS
Ipsen Biopharmaceuticals, Inc $28.3008/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045410147 CMS
E.R. Squibb & Sons, L.L.C. $5,082.0008/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211275 CMS
Kite Pharma, Inc. $29.5908/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270929 CMS
Kite Pharma, Inc. $86.7508/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270937 CMS
E.R. Squibb & Sons, L.L.C. $346.4208/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211315 CMS
E.R. Squibb & Sons, L.L.C. $531.3208/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211327 CMS
E.R. Squibb & Sons, L.L.C. $249.1808/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016211333 CMS
MorphoSys, US Inc. $20.8808/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060326389 CMS
AstraZeneca Pharmaceuticals LP $5,500.0008/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012093715 CMS
Blueprint Medicines Corporation $20.6008/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051255819 CMS
PharmaEssentia USA Corporation $431.2508/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059313821 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $490,006.45 384
PY2020 $388,471.16 261
PY2021 $1,050,838.26 485
PY2022 $1,091,772.71 631
PY2023 $775,978.99 666
PY2024 $571,890.01 512
PY2025 $709,682.37 609

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $18,374.31 4
PY2025 Principal investigator $1,783,451.43 309
PY2024 Recipient $14,342.01 4
PY2024 Principal investigator $2,650,190.68 219
PY2023 Recipient $45,945.53 12
PY2023 Principal investigator $3,151,244.91 146
PY2022 Recipient $24,207.49 10
PY2022 Principal investigator $2,688,028.66 118
PY2021 Recipient $6,310.00 9
PY2021 Principal investigator $2,785,098.97 123
PY2020 Recipient $1,270.00 2
PY2020 Principal investigator $1,044,960.64 164
PY2019 Recipient $11,711.46 7
PY2019 Principal investigator $481,395.12 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

313 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,200.00 12/31/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies No dispute reported 06/30/2026 1202532524
Principal investigator 1 Incyte Corporation $1,000.00 12/29/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240599860
Principal investigator 1 Novartis Pharmaceuticals Corporation $434,274.00 12/18/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment No dispute reported 06/30/2026 1190313979
Principal investigator 1 Genentech, Inc. $2,500.00 12/16/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211677043
Recipient Acrotech Biopharma Inc. $15,750.00 12/11/2025 Covered Recipient Physician SPI-BEL-301 No dispute reported 06/30/2026 1237537867
Principal investigator 1 ABBVIE INC. $2,051.40 12/08/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202529662
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,075.04 12/04/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) No dispute reported 06/30/2026 1190300195
Principal investigator 1 Karyopharm Therapeutics Inc. $455.00 12/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665142
Principal investigator 1 Karyopharm Therapeutics Inc. $813.00 12/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665190
Principal investigator 1 Karyopharm Therapeutics Inc. $455.00 12/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665274
Principal investigator 1 Karyopharm Therapeutics Inc. $500.00 12/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665298
Principal investigator 1 Karyopharm Therapeutics Inc. $1,500.00 12/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665300
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 12/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665310
Principal investigator 1 Karyopharm Therapeutics Inc. $1,250.00 12/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665392
Principal investigator 1 BeOne Medicines Ltd. $259.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190329529
Principal investigator 1 BeOne Medicines Ltd. $1,825.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190329533
Principal investigator 1 BeOne Medicines Ltd. $2,058.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335364
Principal investigator 1 BeOne Medicines Ltd. $10,334.00 11/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335373
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 11/26/2025 Non-covered Recipient Entity
Baylor Rsrch Inst Irb
A Study of Daratumumab No dispute reported 06/30/2026 1175278278
Principal investigator 1 Janssen Research & Development, LLC $8,004.80 11/26/2025 Non-covered Recipient Entity
Baylor Rsrch Inst Irb
A Study of Daratumumab No dispute reported 06/30/2026 1175279628
Principal investigator 1 Janssen Research & Development, LLC $369.85 11/26/2025 Non-covered Recipient Entity
Baylor Rsrch Inst Irb
A Study of Daratumumab No dispute reported 06/30/2026 1175280809
Principal investigator 1 ABBVIE INC. $4,557.80 11/25/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202525384
Principal investigator 1 Genentech, Inc. $2,500.00 11/18/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211677009
Principal investigator 1 ABBVIE INC. $750.00 11/13/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202524233
Principal investigator 1 ABBVIE INC. $500.00 11/13/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202524235
Principal investigator 1 ABBVIE INC. $1,250.00 11/13/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202524237
Principal investigator 1 ABBVIE INC. $1,506.70 11/12/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202523919
Principal investigator 1 BeOne Medicines Ltd. $9,000.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190329531
Principal investigator 1 BeOne Medicines Ltd. $59.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190329537
Principal investigator 1 BeOne Medicines Ltd. $1,804.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190334167
Principal investigator 1 BeOne Medicines Ltd. $198.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335389
Principal investigator 1 BeOne Medicines Ltd. $29.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335398
Principal investigator 1 BeOne Medicines Ltd. $198.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335432
Principal investigator 1 BeOne Medicines Ltd. $408.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335436
Principal investigator 1 BeOne Medicines Ltd. $414.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335452
Principal investigator 1 BeOne Medicines Ltd. $198.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335457
Principal investigator 1 BeOne Medicines Ltd. $9,000.00 11/12/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335466
Principal investigator 1 Epizyme, Inc. $1,125.00 11/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281672
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665144
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665160
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665188
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665206
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665208
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665214
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665236
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665260
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665262
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665290
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665332
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665360
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665362
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665366
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665376
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665398
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665414
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665428
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665430
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665432
Principal investigator 1 Karyopharm Therapeutics Inc. $30.00 11/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665438
Principal investigator 1 BeOne Medicines Ltd. $2,234.00 11/04/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335423
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190329535
Principal investigator 1 BeOne Medicines Ltd. $822.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190329539
Principal investigator 1 BeOne Medicines Ltd. $2,058.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335359
Principal investigator 1 BeOne Medicines Ltd. $9,628.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335378
Principal investigator 1 BeOne Medicines Ltd. $2,234.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335394
Principal investigator 1 BeOne Medicines Ltd. $2,058.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335411
Principal investigator 1 BeOne Medicines Ltd. $2,234.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335415
Principal investigator 1 BeOne Medicines Ltd. $1,825.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335428
Principal investigator 1 BeOne Medicines Ltd. $5,470.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335444
Principal investigator 1 BeOne Medicines Ltd. $1,825.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335448
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335461
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/28/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335471
Principal investigator 1 Genentech, Inc. $2,500.00 10/27/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676947
Principal investigator 1 ABBVIE INC. $1,200.00 10/22/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202518175
Principal investigator 1 ABBVIE INC. $29,291.60 10/16/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202517377
Principal investigator 1 BeOne Medicines Ltd. $9,000.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335369
Principal investigator 1 BeOne Medicines Ltd. $9,000.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335384
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335403
Principal investigator 1 BeOne Medicines Ltd. $408.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335407
Principal investigator 1 BeOne Medicines Ltd. $499.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335419
Principal investigator 1 BeOne Medicines Ltd. $9,000.00 10/07/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190335440
Principal investigator 1 Novartis Pharmaceuticals Corporation $130,282.20 10/06/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190307761
Principal investigator 1 Karyopharm Therapeutics Inc. $813.00 10/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665156
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 10/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665292
Principal investigator 1 Karyopharm Therapeutics Inc. $549.00 10/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665350
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 10/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665388
Principal investigator 1 Karyopharm Therapeutics Inc. $2,283.00 10/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665472
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,471.62 10/01/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190301351
Principal investigator 1 ABBVIE INC. $500.00 09/30/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202512898
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 09/29/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190336710
Principal investigator 1 Genentech, Inc. $2,500.00 09/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676902
Principal investigator 1 Genentech, Inc. $2,500.00 09/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676910
Principal investigator 1 Epizyme, Inc. $1,125.00 09/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281426
Recipient ABBVIE INC. $1,875.00 09/10/2025 Covered Recipient Physician A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202399641
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,001.14 09/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190311955
Principal investigator 1 Novartis Pharmaceuticals Corporation $473.64 09/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment No dispute reported 06/30/2026 1190311959
Principal investigator 1 ABBVIE INC. $5,675.54 09/04/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202509708
Principal investigator 1 ABBVIE INC. $10,393.50 09/04/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202509710
Principal investigator 1 Karyopharm Therapeutics Inc. $2,276.00 09/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665226
Principal investigator 1 BeOne Medicines Ltd. $5,122.00 09/02/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190334171
Principal investigator 1 Janssen Research & Development, LLC $163.00 08/18/2025 Non-covered Recipient Entity
Baylor Rsrch Inst Irb
A Study of Daratumumab No dispute reported 06/30/2026 1175280027
Principal investigator 1 ABBVIE INC. $266.50 08/06/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202502450
Recipient Novartis Pharmaceuticals Corporation $263.17 08/05/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190293178
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665140
Principal investigator 1 Karyopharm Therapeutics Inc. $4,079.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665150
Principal investigator 1 Karyopharm Therapeutics Inc. $2,982.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665154
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665172
Principal investigator 1 Karyopharm Therapeutics Inc. $96.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665174
Principal investigator 1 Karyopharm Therapeutics Inc. $2,276.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665176
Principal investigator 1 Karyopharm Therapeutics Inc. $2,283.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665186
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665222
Principal investigator 1 Karyopharm Therapeutics Inc. $1,359.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665228
Principal investigator 1 Karyopharm Therapeutics Inc. $2,276.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665238
Principal investigator 1 Karyopharm Therapeutics Inc. $96.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665244
Principal investigator 1 Karyopharm Therapeutics Inc. $190.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665264
Principal investigator 1 Karyopharm Therapeutics Inc. $96.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665270
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665286
Principal investigator 1 Karyopharm Therapeutics Inc. $1,359.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665330
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665354
Principal investigator 1 Karyopharm Therapeutics Inc. $813.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665400
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665410
Principal investigator 1 Karyopharm Therapeutics Inc. $190.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665458
Principal investigator 1 Karyopharm Therapeutics Inc. $1,359.00 08/04/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665480
Principal investigator 1 Genentech, Inc. $6,340.00 07/29/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676816
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,881.51 07/28/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190311949
Principal investigator 1 ABBVIE INC. $4,875.00 07/24/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202499474
Principal investigator 1 Genentech, Inc. $2,500.00 07/24/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676804
Principal investigator 1 Acerta Pharma LLC $13,346.00 07/09/2025 Non-covered Recipient Entity
BAYLOR SCOTT AND WHITE RESEARCH INSTITUTE
Part 1 FL An Open label Phase 1b Study of ACP196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma Part 2 MZL An Open label Phase 1b or 2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent Bcell Non Hodgkin Lymphoma No dispute reported 06/30/2026 1185555752
Principal investigator 1 Karyopharm Therapeutics Inc. $455.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665194
Principal investigator 1 Karyopharm Therapeutics Inc. $4,079.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665278
Principal investigator 1 Karyopharm Therapeutics Inc. $1,359.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665304
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665306
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665336
Principal investigator 1 Karyopharm Therapeutics Inc. $2,515.50 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665352
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665374
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665380
Principal investigator 1 Karyopharm Therapeutics Inc. $455.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665390
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665416
Principal investigator 1 Karyopharm Therapeutics Inc. $1,359.00 07/03/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665482
Principal investigator 1 ABBVIE INC. $6,194.00 07/02/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202493983
Principal investigator 1 BeOne Medicines Ltd. $198.00 06/17/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326856
Principal investigator 1 BeOne Medicines Ltd. $198.00 06/17/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326862
Principal investigator 1 BeOne Medicines Ltd. $9,000.00 06/17/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326866
Principal investigator 1 Acerta Pharma LLC $156.00 06/16/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INST
Part 1 FL An Open label Phase 1b Study of ACP196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma Part 2 MZL An Open label Phase 1b or 2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent Bcell Non Hodgkin Lymphoma No dispute reported 06/30/2026 1185555748
Principal investigator 1 BeOne Medicines Ltd. $32.00 06/10/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326852
Principal investigator 1 BeOne Medicines Ltd. $29.00 06/10/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326854
Principal investigator 1 BeOne Medicines Ltd. $198.00 06/10/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326858
Principal investigator 1 BeOne Medicines Ltd. $59.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326860
Principal investigator 1 BeOne Medicines Ltd. $198.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190326864
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665280
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665282
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665294
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665314
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665328
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 06/02/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665346
Principal investigator 1 BeOne Medicines Ltd. $1,804.00 05/30/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190331019
Principal investigator 1 Epizyme, Inc. $2,145.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281218
Principal investigator 1 Epizyme, Inc. $2,130.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281228
Principal investigator 1 Epizyme, Inc. $2,213.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281238
Principal investigator 1 Epizyme, Inc. $1,847.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281240
Principal investigator 1 Genentech, Inc. $3,889.00 05/28/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676672
Principal investigator 1 Genentech, Inc. $49,853.00 05/14/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676749
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,016.00 05/07/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INST
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185555746
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665202
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665216
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665224
Principal investigator 1 Karyopharm Therapeutics Inc. $4,079.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665248
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665254
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665256
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665368
Principal investigator 1 Karyopharm Therapeutics Inc. $2,982.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665370
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665394
Principal investigator 1 Karyopharm Therapeutics Inc. $2,982.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665422
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665450
Principal investigator 1 Karyopharm Therapeutics Inc. $4,079.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665462
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.30 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665464
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665484
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 05/05/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665492
Principal investigator 1 Epizyme, Inc. $27.00 05/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281200
Principal investigator 1 ABBVIE INC. $6,537.70 04/30/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202480509
Principal investigator 1 Epizyme, Inc. $41.00 04/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184281036
Principal investigator 1 BeiGene, Ltd. $1,514.00 04/17/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190323126
Principal investigator 1 Celgene Corporation $2,500.00 04/16/2025 Non-covered Recipient Entity
Texas Onco Southwest Fort Worth
Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. No dispute reported 06/30/2026 1222304637
Principal investigator 1 Genentech, Inc. $10,971.00 04/16/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676762
Principal investigator 1 Genentech, Inc. $379.00 04/08/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676754
Principal investigator 1 ABBVIE INC. $4,525.91 04/03/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202469735
Principal investigator 1 Acerta Pharma LLC $12,513.00 03/26/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INST
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma No dispute reported 06/30/2026 1185555750
Principal investigator 1 Epizyme, Inc. $2,674.00 03/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280836
Principal investigator 1 Genentech, Inc. $379.00 03/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676783
Principal investigator 1 Epizyme, Inc. $4,991.00 03/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280838
Principal investigator 1 BeiGene, Ltd. $1,804.00 03/18/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190323124
Principal investigator 1 ABBVIE INC. $1,517.10 03/13/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202463665
Principal investigator 1 ABBVIE INC. $6,220.40 03/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202461948
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 03/06/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665180
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 03/06/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665184
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 03/06/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665198
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 03/06/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665338
Principal investigator 1 Karyopharm Therapeutics Inc. $2,515.50 03/06/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665446
Principal investigator 1 Karyopharm Therapeutics Inc. $1,539.00 03/06/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665452
Principal investigator 1 Karyopharm Therapeutics Inc. $1,359.00 03/06/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665474
Principal investigator 1 BeiGene, Ltd. $4,319.43 03/04/2025 Non-covered Recipient Entity
Baylor Research Institute
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322012
Principal investigator 1 ABBVIE INC. $1,517.10 02/27/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202454460
Principal investigator 1 ABBVIE INC. $4,353.70 02/27/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202454464
Principal investigator 1 ABBVIE INC. $4,353.70 02/25/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202453831
Principal investigator 1 BeiGene, Ltd. $10,555.00 02/25/2025 Non-covered Recipient Entity
Texas Oncology-Amarillo Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib No dispute reported 06/30/2026 1190323122
Principal investigator 1 Epizyme, Inc. $1,485.00 02/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280822
Principal investigator 1 Epizyme, Inc. $2,446.00 02/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280824
Principal investigator 1 Epizyme, Inc. $1,847.00 02/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280826
Principal investigator 1 Genentech, Inc. $2,500.00 02/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676688
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $35,252.93 02/12/2025 Non-covered Recipient Entity
Baylor Research Institute
A Phase III, Open-Label, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy followed by Rituximab in Subjects with Previously Untreated Follicular Lymphoma No dispute reported 06/30/2026 1235998736
Principal investigator 1 Karyopharm Therapeutics Inc. $2,276.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665146
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665148
Principal investigator 1 Karyopharm Therapeutics Inc. $813.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665152
Principal investigator 1 Karyopharm Therapeutics Inc. $2,982.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665162
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665168
Principal investigator 1 Karyopharm Therapeutics Inc. $4,105.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665170
Principal investigator 1 Karyopharm Therapeutics Inc. $1,539.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665182
Principal investigator 1 Karyopharm Therapeutics Inc. $65.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665196
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665200
Principal investigator 1 Karyopharm Therapeutics Inc. $4,105.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665210
Principal investigator 1 Karyopharm Therapeutics Inc. $1,825.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665212
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665218
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665220
Principal investigator 1 Karyopharm Therapeutics Inc. $455.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665234
Principal investigator 1 Karyopharm Therapeutics Inc. $1,539.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665242
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.30 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665250
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665252
Principal investigator 1 Karyopharm Therapeutics Inc. $4,105.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665258
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665266
Principal investigator 1 Karyopharm Therapeutics Inc. $4,079.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665268
Principal investigator 1 Karyopharm Therapeutics Inc. $1,825.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665276
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665284
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665288
Principal investigator 1 Karyopharm Therapeutics Inc. $1,525.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665296
Principal investigator 1 Karyopharm Therapeutics Inc. $1,825.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665302
Principal investigator 1 Karyopharm Therapeutics Inc. $1,275.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665308
Principal investigator 1 Karyopharm Therapeutics Inc. $2,982.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665316
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665320
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665326
Principal investigator 1 Karyopharm Therapeutics Inc. $4,105.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665334
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665340
Principal investigator 1 Karyopharm Therapeutics Inc. $4,105.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665344
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665348
Principal investigator 1 Karyopharm Therapeutics Inc. $1,825.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665358
Principal investigator 1 Karyopharm Therapeutics Inc. $4,105.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665364
Principal investigator 1 Karyopharm Therapeutics Inc. $1,275.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665372
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665378
Principal investigator 1 Karyopharm Therapeutics Inc. $548.60 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665382
Principal investigator 1 Karyopharm Therapeutics Inc. $548.60 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665384
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665386
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665396
Principal investigator 1 Karyopharm Therapeutics Inc. $1,825.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665402
Principal investigator 1 Karyopharm Therapeutics Inc. $1,539.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665406
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665408
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665412
Principal investigator 1 Karyopharm Therapeutics Inc. $1,539.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665418
Principal investigator 1 Karyopharm Therapeutics Inc. $1,525.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665420
Principal investigator 1 Karyopharm Therapeutics Inc. $1,525.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665424
Principal investigator 1 Karyopharm Therapeutics Inc. $1,825.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665426
Principal investigator 1 Karyopharm Therapeutics Inc. $1,359.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665434
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665436
Principal investigator 1 Karyopharm Therapeutics Inc. $1,275.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665440
Principal investigator 1 Karyopharm Therapeutics Inc. $1,525.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665442
Principal investigator 1 Karyopharm Therapeutics Inc. $1,525.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665444
Principal investigator 1 Karyopharm Therapeutics Inc. $1,457.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665448
Principal investigator 1 Karyopharm Therapeutics Inc. $548.60 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665454
Principal investigator 1 Karyopharm Therapeutics Inc. $1,275.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665456
Principal investigator 1 Karyopharm Therapeutics Inc. $2,515.50 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665460
Principal investigator 1 Karyopharm Therapeutics Inc. $1,275.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665466
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665468
Principal investigator 1 Karyopharm Therapeutics Inc. $2,276.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665476
Principal investigator 1 Karyopharm Therapeutics Inc. $2,515.50 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665478
Principal investigator 1 Karyopharm Therapeutics Inc. $1,275.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665486
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665488
Principal investigator 1 Karyopharm Therapeutics Inc. $1,426.00 02/12/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665490
Principal investigator 1 Eli Lilly and Company $520.21 02/10/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187892694
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 02/07/2025 Non-covered Recipient Entity
Baylor Rsrch Inst Irb
A Study of Daratumumab No dispute reported 06/30/2026 1175278866
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 02/07/2025 Non-covered Recipient Entity
Baylor Rsrch Inst Irb
A Study of Daratumumab No dispute reported 06/30/2026 1175279899
Principal investigator 1 ABBVIE INC. $9,484.76 02/06/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202448554
Principal investigator 1 Acerta Pharma LLC $108.00 02/05/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INST
A Phase 1b Multicenter Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma No dispute reported 06/30/2026 1185555754
Principal investigator 1 Genentech, Inc. $31,416.00 01/28/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676692
Principal investigator 1 Genentech, Inc. $38,864.00 01/28/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL No dispute reported 06/30/2026 1211676723
Recipient Novartis Pharmaceuticals Corporation $486.14 01/28/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190293182
Principal investigator 1 Karyopharm Therapeutics Inc. $4,079.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665158
Principal investigator 1 Karyopharm Therapeutics Inc. $190.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665164
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665166
Principal investigator 1 Karyopharm Therapeutics Inc. $65.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665178
Principal investigator 1 Karyopharm Therapeutics Inc. $190.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665192
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665204
Principal investigator 1 Karyopharm Therapeutics Inc. $96.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665230
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665232
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665240
Principal investigator 1 Karyopharm Therapeutics Inc. $65.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665246
Principal investigator 1 Karyopharm Therapeutics Inc. $190.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665272
Principal investigator 1 Karyopharm Therapeutics Inc. $96.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665312
Principal investigator 1 Karyopharm Therapeutics Inc. $4,079.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665318
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665322
Principal investigator 1 Karyopharm Therapeutics Inc. $1,359.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665324
Principal investigator 1 Karyopharm Therapeutics Inc. $4,079.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665342
Principal investigator 1 Karyopharm Therapeutics Inc. $2,283.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665356
Principal investigator 1 Karyopharm Therapeutics Inc. $2,516.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665404
Principal investigator 1 Karyopharm Therapeutics Inc. $65.00 01/20/2025 Non-covered Recipient Entity
Texas Oncology, P.A - Research Department
A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis No dispute reported 06/30/2026 1246665470
Principal investigator 1 Incyte Corporation $2,500.00 01/10/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240599847
Principal investigator 1 Incyte Corporation $1,000.00 01/10/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240599850
Principal investigator 1 Incyte Corporation $10,250.00 01/10/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240599854
Principal investigator 1 Incyte Corporation $2,000.00 01/10/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY-BAYLOR SAMMONS CANCER CENTER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis No dispute reported 06/30/2026 1240599856
Principal investigator 1 Novartis Pharmaceuticals Corporation $201,019.12 01/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase No dispute reported 06/30/2026 1190311957
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,728.15 01/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase 3, Randomized, Double-blind, Study to Assess Efficacy and Safety of Ianalumab (VAY736) Versus Placebo in Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Who Failed at Least One Line of Treatment No dispute reported 06/30/2026 1190311961
Principal investigator 1 Epizyme, Inc. $1,005.00 01/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280792
Principal investigator 1 Epizyme, Inc. $3,613.00 01/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280794
Principal investigator 1 Epizyme, Inc. $1,720.00 01/08/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184280800
Principal investigator 1 Janssen Research & Development, LLC $3,900.00 01/03/2025 Non-covered Recipient Entity
Baylor Rsrch Inst Irb
A Study of Daratumumab No dispute reported 06/30/2026 1175280908
Principal investigator 1 Novartis Pharmaceuticals Corporation $111,692.98 01/01/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190311951